Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

Gynecologic oncology - 1 Aug 2003

Gemignani Mary L, Schlaerth Alan C, Bogomolniy Faina, Barakat Richard R, Lin Oscar, Soslow Robert, Venkatraman Ennapandam, Boyd Jeff

Abstract excerpt

OBJECTIVES: The goals of this study were to perform a comprehensive assessment of the prevalence of KRAS oncogene mutations in invasive epithelial ovarian carcinomas of various histologic subtypes, and for any subgroup(s) in which KRAS mutation was found to be common, to address the hypothesis th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous
Share to BRAF gene
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Mutation

Share to Oncogene Proteins

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 12893203
DOI: 10.1016/s0090-8258(03)00264-6

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12893203-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.PMID 12893203Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Semantic proximity Read ↗

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.Semantic proximity Read ↗

Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.Semantic proximity Read ↗

BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas.Semantic proximity Read ↗

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.Semantic proximity Read ↗

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Semantic proximity Read ↗

K-ras mutations in mucinous ovarian tumorsSemantic proximity Read ↗

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.Semantic proximity Read ↗

Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.Semantic proximity Read ↗

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.Semantic proximity Read ↗

Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.